Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong […]
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong […]
